Target Identification of the Hepatocellular Carcinoma-Specific Aptamer JHIT2e and Construction of Engineered Nanotrains for Synergistic Chemoradiotherapy
Molecular Pharmaceutics · 02.02.2026 · 23 (2) · 893-904
DOI: 10.1021/acs.molpharmaceut.5c01251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 23.01.2026. Verfasst von Jiangkun Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Aptamers, Nucleotide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Zhuhai People?s Hospital, Zhuhai Science and Technology Innovation Bureau, Guangdong Medical Science and Technology Research Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) demands advanced multimodal therapies to overcome heterogeneity-driven treatment resistance. Although aptamers exhibit superior targeting advantages over antibodies, their clinical translation remains severely hindered by ambiguous target identification and the limited drug-loading capacity of direct aptamer-drug conjugates. To address this, we first identified vascular endothelial growth factor receptor 2 (VEGFR2) as the target of the HCC-specific aptamer JHIT2e using an integrated approach combining 3D photo-cross-linking chip technology, surface plasmon resonance (SPR), and liquid chromatography-mass spectrometry (LC-MS). Building on this, we engineered a multifunctional DNA nanotrain (131I-NTs-Dox, namely, 131I-labeled DNA nanotrains loaded with doxorubicin) comprising three key components: the JHIT2e aptamer as a navigation module for tumor-specific targeting, hybridization chain reaction (HCR)-assembled dsDNA duplexes as "carriages" intercalated with doxorubicin (Dox), and carboxyfluorescein (FAM)-terminated termini radiolabeled with iodine-131 (131I) via an optimized chloramine T method. Notably, this FAM-mediated labeling strategy significantly enhanced radiolabeling efficiency to 93%, surpassing conventional tyrosine-based methods (70-85%). Each nanotrain entity achieved an unprecedented payload capacity of 50 Dox molecules and 80 131I atoms. In vitro studies demonstrated that 131I-NTs-Dox exhibits specific affinity for HepG2 cells, rapid lysosomal endocytosis, and enhanced tumor accumulation. Furthermore, the platform synergistically inhibited HCC cell viability through dual chemoradiotherapeutic mechanisms: Dox-induced DNA repair inhibition and 131I-mediated DNA damage. Collectively, 131I-NTs-Dox represents a scalable nanoplatform with high-precision HCC targeting, dual-modal therapeutic efficacy, and promising clinical potential for chemoradiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, Guangdong 519099, China.
- Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China.
ORCID-Profile: Shisong Han
Förderung
- Zhuhai People?s Hospital
- Zhuhai Science and Technology Innovation Bureau
- Guangdong Medical Science and Technology Research Foundation
Zitieren
APA
Yu, J., Lin, X., Huang, W., Han, S., Qin, J., & Xu, J. H. (2026). Target Identification of the Hepatocellular Carcinoma-Specific Aptamer JHIT2e and Construction of Engineered Nanotrains for Synergistic Chemoradiotherapy. Molecular Pharmaceutics, 23(2), 893-904. https://doi.org/10.1021/acs.molpharmaceut.5c01251
Vancouver
Yu J, Lin X, Huang W, Han S, Qin J, Xu JH. Target Identification of the Hepatocellular Carcinoma-Specific Aptamer JHIT2e and Construction of Engineered Nanotrains for Synergistic Chemoradiotherapy. Molecular Pharmaceutics. 2026;23(2):893-904. doi:10.1021/acs.molpharmaceut.5c01251
BibTeX
@article{Yu2026,
author = {Yu, Jiangkun and Lin, Xue and Huang, Wenshan and Han, Shisong and Qin, Jie and Xu, Jie-Hua},
title = {Target Identification of the Hepatocellular Carcinoma-Specific Aptamer JHIT2e and Construction of Engineered Nanotrains for Synergistic Chemoradiotherapy},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {2},
pages = {893--904},
doi = {10.1021/acs.molpharmaceut.5c01251}
}
EUVIMED